Bevacizumab or ranibizumab most commonly used angiogenesis inhibitors used for age-related macular degeneration, diabetic retinopathy, several vascular disorders of ophthalmology particularly retinal diseases. Currently available injection of these drugs i.e Bevacizumab or ranibizumab are required to be repeatedly injected into vitreous cavity in several of these patients due to short effect lasting few months and this add extra financial burden to patients and their family. Why pharmacology researchers or drug industries have not succeeded in producing bevacizumab or ranibizumab having slow sustained release i.e implant or liposomal encapsulated delivery system?
It is no need for slow sustained release VEGF since short acting currently used substances Avastin, ranibizumab also causes systemic side effects presented in many papers. The last one I am sending for your attention.
- Badges
- Science topic
- Similar topics
- Chemistry
- Pharmacology